ABVC BioPharma
ABVC
5 hedge funds and large institutions have $1.56M invested in ABVC BioPharma in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 6 closing their positions.
199% more capital invested
Capital invested by funds: $521K → $1.56M (+$1.03M)
0.16% more ownership
Funds ownership: 0% → 0.16% (+0.16%)
44% less funds holding
Funds holding: 9 → 5 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.04M |
| 2 |
VF
Virtu Financial
New York
|
+$41.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$24K |
| 4 |
Morgan Stanley
New York
|
+$4.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$165K |
| 2 |
Squarepoint
New York
|
-$44K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$35K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$27K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $1.26M | +$1.04M | +33,220 | +819% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $169K | – | – | – |
|
|
VF
3
Virtu Financial
New York
| $92K | +$41.8K | +1,333 | +96% |
|
|
4
UBS Group
Zurich,
Switzerland
| $26K | +$24K | +766 | New |
|
|
5
Morgan Stanley
New York
| $5K | +$4.67K | +149 | New |
|
|
SM
6
Sabby Management
Miami Beach,
Florida
| – | -$165K | -7,156 | Closed |
|
|
7
Squarepoint
New York
| – | -$44K | -1,921 | Closed |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$35K | -1,508 | Closed |
|
|
CS
9
Credit Suisse
Zurich,
Switzerland
| – | -$27K | -1,171 | Closed |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | -$8K | -349 | Closed |
|
11
Bank of America
Charlotte,
North Carolina
| – | -$1K | -49 | Closed |
|
ABVC Hedge Fund Activity: Q4 2021 in Review
5 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q4 2021, worth a combined $1.56M — up 199% from $521K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ABVC and 2 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $1.04M. The largest seller was Sabby Management, exiting entirely with an estimated $165K sold.
- 5 institutional investors held ABVC BioPharma (ABVC) as of Q4 2021, down from 9 in Q3 2021.
- Funds reported $1.56M of ABVC BioPharma stock for Q4 2021, up 199% quarter-over-quarter.
- 2 funds opened new ABVC BioPharma positions in Q4 2021 and 6 closed out, a net change of -4 holders.
- The largest ABVC BioPharma buyer in Q4 2021 was Vanguard Group, an estimated $1.04M added.
- The largest ABVC BioPharma seller in Q4 2021 was Sabby Management, an estimated $165K sold.
Based on aggregated 13F filings for Q4 2021.